SARS-CoV-2 vaccine, viral vector (Pending FDA Approval)

Brand and Other Names:COVID-19 vaccine, viral vector
  • Print
Sections

Dosing & Uses

COVID-19 Disease Prevention

Pending FDA approval for prevention of coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Several vaccines are in late phase 3 clinical trials in the United States

Next:

Pharmacology

Mechanism of Action

The goal is to elicit long-term antigen-specific antibody responses by plasma cells and to develop persistent T-cell and B-cell memory of the antigen (ie, humoral and cellular immune response)

Viral vector technology involves the delivery of ≥1 genes that encode a target antigen within an unrelated, engineered virus (eg, adenovirus, measles vaccine [MV])

These types of vaccines are likely to be developed more slowly than nucleic acid (genetic code) vaccines owing to the need for biosafety level 2 (BSL2) laboratories

The concern of possible preexisting immunity in vaccine recipients to viral vectors (eg Ad5, MV) decreasing vaccine effectiveness have been avoided by using low human prevalence adenoviral serotypes (Ad26, Ad35)

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.